- Home
- RLYB vs IGC Comparison
RLYB vs IGC Comparison
Compare RLYB & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLYB | IGC |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7M | 28.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RLYB | IGC |
|---|---|---|
| Price | $4.71 | $0.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 23.8K | ★ 421.1K |
| Earning Date | 03-12-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $674,000.00 | ★ $1,106,000.00 |
| Revenue This Year | $17.61 | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.71 | N/A |
| 52 Week Low | $1.76 | $0.24 |
| 52 Week High | $6.99 | $0.50 |
Technical Indicators
Market Signals| Indicator | RLYB | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 94.88 | 42.70 |
| Support Level | $0.56 | $0.27 |
| Resistance Level | $5.37 | $0.30 |
| Average True Range (ATR) | 0.17 | 0.01 |
| MACD | 0.49 | -0.00 |
| Stochastic Oscillator | 89.81 | 38.38 |
Price Performance
Historical ComparisonAbout RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.